ACTH-Derived Neuropeptide
What is Semax?
Semax is a synthetic heptapeptide (Met-Glu-His-Phe-Pro-Gly-Pro) derived from the N-terminal fragment of adrenocorticotropic hormone (ACTH 4–7), with the addition of a proline-glycine-proline C-terminal extension that dramatically increases its metabolic stability. It was developed in Russia and has been approved for clinical use in Russia and Ukraine.
Mechanism of Action
Semax exerts its effects primarily through upregulation of Brain-Derived Neurotrophic Factor (BDNF) and its high-affinity receptor TrkB, as well as nerve growth factor (NGF). It has documented effects on serotonin, dopamine, and cholinergic neurotransmitter systems. It also exhibits notable anti-inflammatory activity in neurological tissue.
Cognitive Research
Research suggests Semax may enhance working memory, attention, and executive function. Studies in models of cognitive impairment have shown improvements in learning and recall. Its BDNF-upregulating mechanism has made it of interest in research on neuroplasticity and neuroprotection.
Neuroprotective Research
Semax has been studied in the context of ischaemic stroke recovery, optic nerve disease, and neurodegenerative conditions. In Russia, it is approved for use in ischaemic stroke management. Preclinical data suggests it may promote neuronal survival under hypoxic conditions.
Storage & Handling
Lyophilised Semax should be stored at 2–8°C. Once reconstituted, it should be used within a short period or stored frozen. It is typically administered intranasally in research settings.
Research Disclaimer: Semax is approved for clinical use in Russia and Ukraine. In most other jurisdictions, including India, it is used as a research compound only. This content is for educational purposes and does not constitute medical advice.